Oxymorphone conversion reference
Check OpioidCalc's OME factors by route, then open the formulation-specific pharmacology, cautions and supporting sources.
Educational reference for qualified healthcare professionals. Conversion factors estimate oral morphine equivalent daily dose. They are not a recommended switching dose. Confirm the result with a current source and local guidance.
Free download · iOS and Android · Optional Pro features
Current OpioidCalc factors
Multiply the dose or delivery rate in the stated units by the factor to estimate mg oral morphine equivalent per day. These are the factors currently used by OpioidCalc. Methadone uses 4.7 when converting methadone to OME.
| Route | Input units | OME factor |
|---|---|---|
| Oral | mg/day | 3 |
Compare a complete regimen in the app
Formulations and cautions
Choose a formulation to read its pharmacology, population, limitations and source references.
OralDefault in appImmediate-release tablet
App source review: 27 August 2026
View details and sources
Immediate-release tablet
App source review: 27 August 2026
View details and sources- Elimination half-life
- Approximately 9 to 11 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Steady state
- 3 days
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Bioavailability
- Approximately 10%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information12.1 Mechanism of Action. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Metabolism
- Hepatic reduction and glucuronidation form oxymorphone-3-glucuronide and 6-hydroxy-oxymorphone.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Active metabolites
- 6-hydroxy-oxymorphone is active in animals; its human analgesic contribution is not established.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Elimination
- Less than 1% is excreted unchanged; urinary glucuronide elimination is substantial.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Renal impairment increased bioavailability by about 26% to 65% in cited studies.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information8.7 Renal Impairment. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Hepatic impairment can markedly increase bioavailability.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride immediate-release tablet prescribing information8.6 Hepatic Impairment. United States. Source revised 29 June 2026. App review 27 August 2026. Regulatory product information.
OralModified-release tablet
App source review: 27 August 2026
View details and sources
Modified-release tablet
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- Median 2 hours after a fasting 40 mg dose
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- Approximately 9 to 11 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Steady state
- 3 days
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Bioavailability
- Approximately 10%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Formulation behaviour
- Every-12-hour extended-release tablet.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: The dosing interval is not proof of clinical effect duration.
- Oxymorphone hydrochloride extended-release tablet prescribing information2 and 12.3. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.1 Mechanism of Action. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Metabolism
- Hepatic reduction and glucuronidation form oxymorphone-3-glucuronide and 6-hydroxy-oxymorphone.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Active metabolites
- 6-hydroxy-oxymorphone is active in animals; its human analgesic contribution is not established.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Elimination
- Less than 1% is excreted unchanged; urinary glucuronide elimination is substantial.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Renal impairment increased bioavailability by about 26% to 65% in cited studies.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information8.7 Renal Impairment. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Hepatic impairment can markedly increase bioavailability.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxymorphone hydrochloride extended-release tablet prescribing information8.6 Hepatic Impairment. United States. Source revised 15 January 2026. App review 27 August 2026. Regulatory product information.
Sources used on this page
Other medicine references
Use the full calculator
Compare opioid regimens and inspect formulation-specific information in OpioidCalc for iOS and Android.